CFTR Modulator Response in Nasal Organoids Derived from People with Cystic Fibrosis
Cells · 02.12.2025 · 14 (23) · 1914
DOI: 10.3390/cells14231914 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 02.12.2025. Verfasst von Stefania Lo Cicero und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Organoids, Nasal Mucosa. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union - NextGenerationEU through the Italian Ministry of University and Research under PNRR, Italian Cystic Fibrosis Foundation, Ministero dell'Università e della Ricerca - PRIN 2022.
Abstract (Originalsprache)
Despite the progressive extension of CFTR variant eligibility to the triple combination of elexacaftor/tezacaftor/ivacaftor (ETI), most rare CFTR pathogenic variants remain ineligible for CFTR modulators. It is crucial to determine whether unexplored variants are rescuable by clinical modulators and to identify innovative therapeutic strategies for rescuing non-responder variants. The approach known as “theratyping” (in vitro testing of genotypes) has been accepted by the Food and Drug Administration (FDA) for the extension of clinical modulators’ approval for in vitro responding genotypes. We used one of the most advanced models for theratyping: organoids derived from nasal epithelia of people with cystic fibrosis (pwCF). We optimized the forskolin-induced swelling (FIS) of organoids to assess CFTR basal or modulator-restored function. Nasal organoids mimicked the original epithelial tissue, CFTR residual activity, and modulator response. We set up the FIS assay using nasal organoids with reference genotypes and theratyped 38 rare (non-F508del) CFTR genotypes, either eligible or non-eligible for FDA approval, for treatment with ETI or ivacaftor. We found strong correspondence between the in vitro response of CFTR variants to modulators and their FDA approval status. Additionally, some previously uncharacterized CFTR variants have proven responsive to clinical modulators, with significant therapeutic implications. These results suggest that the nasal organoid FIS assay, pending confirmation of the prediction in the corresponding pwCF, might be considered as a powerful in vitro tool to predict modulator efficacy in each pwCF, guiding out-of-label prescription in CF, and to identify uncharacterized variants responsive to modulators. This approach may allow comparison of the efficacy of different therapeutics or the identification of innovative strategies for non-responding genotypes, improving personalized therapy and quality of life for pwCF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.
- Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
- Confocal Microscopy Unit, Core Facilities, Istituto Superiore di Sanità, 00161 Rome, Italy.
- Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, 80131 Naples, Italy.
- CEINGE Biotecnologie Avanzate Franco Salvatore S.c.a.r.l., 80145 Naples, Italy.
- Cystic Fibrosis Centre, Azienda Ospedaliera Universitaria Integrata Verona, 37126 Verona, Italy.
ORCID-Profile: Germana Castelli, Aurora Ceci, Giovanna Blaconà, Francesca Spadaro, Felice Amato, Paola Melotti, Claudio Sorio, Marco Lucarelli
Förderung
- European Union - NextGenerationEU through the Italian Ministry of University and Research under PNRR
- Italian Cystic Fibrosis Foundation
- Ministero dell'Università e della Ricerca - PRIN 2022
- Pasteur Institute Cenci Bolognetti Foundation
- European Union—NextGenerationEU
- Italian Ministry of University and Research
- Ministero dell’Università e della Ricerca
Zitieren
APA
Lo Cicero, S., Castelli, G., Ceci, A., Cerio, A. M., Blaconà, G., Virgulti, M., Allushi, S., Sette, G., Spadaro, F., Amato, F., Melotti, P., Sorio, C., Cimino, G., Biffoni, M., Lucarelli, M., & Eramo, A. (2025). CFTR Modulator Response in Nasal Organoids Derived from People with Cystic Fibrosis. Cells, 14(23), 1914. https://doi.org/10.3390/cells14231914
Vancouver
Lo Cicero S, Castelli G, Ceci A, Cerio AM, Blaconà G, Virgulti M, et al. CFTR Modulator Response in Nasal Organoids Derived from People with Cystic Fibrosis. Cells. 2025;14(23):1914. doi:10.3390/cells14231914
BibTeX
@article{LoCicero2025,
author = {Lo Cicero, Stefania and Castelli, Germana and Ceci, Aurora and Cerio, Anna Maria and Blaconà, Giovanna and Virgulti, Mariarita and Allushi, Sara and Sette, Giovanni and Spadaro, Francesca and Amato, Felice and Melotti, Paola and Sorio, Claudio and Cimino, Giuseppe and Biffoni, Mauro and Lucarelli, Marco and Eramo, Adriana},
title = {CFTR Modulator Response in Nasal Organoids Derived from People with Cystic Fibrosis},
journal = {Cells},
year = {2025},
volume = {14},
number = {23},
pages = {1914},
doi = {10.3390/cells14231914}
}
EUVIMED